Takeda pharmaceuticals news
Takeda said it plans to “reduce and concentrate” its R&D in Japan and the U.S. Takeda’s R&D organization will now be a “dual-centered” structure in Japan and Boston, with “lean regional centers” to help manage local studies and regional issues with global studies. Takeda acknowledged a headcount reduction, but declined to say how many jobs would be affected. Takeda said it will focus its emphasis on operational efficiency, including restructuring R&D and optimizing relationships among its R&D, business and corporate functions.
Its R&D site in Shonan, Japan, will focus on CNS and regenerative medicines. Takeda plans to convert the site into a research park that houses scientists from other companies and institutions. The pharma also plans to create JVs and form spin-offs to address specific disease areas. At its Boston site, Takeda will conduct R&D on oncology and GI disease, as well as immunomodulation as it relates to its core therapeutic areas. The site will be Takeda’s development center and the primary home of its translational research and early clinical group. Takeda said a “smaller biotech-like site” in San Diego will develop specialized technologies in the GI and CNS areas. ...